Electra Therapeutics, Inc. (ETRA) stock
ETRANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 12, 2026
$8.94+0.51 (+6.05%)
Close on Nov 19, 2026Market cap $562.03MP/E –Yield –
Electra Therapeutics net income
Net income is the profit left for shareholders after every expense, interest and tax.
Quarterly net income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$23.93M | – |
| Q2 FY2026 | Jun 30, 2026 | -$26.75M | – |
| Q1 FY2026 | Mar 31, 2026 | -$22.17M | – |
| Q3 FY2025 | Sep 30, 2025 | -$18.09M | – |
| Q2 FY2025 | Jun 30, 2025 | -$17.58M | – |
| Q1 FY2025 | Mar 31, 2025 | -$7.79M | – |
See a number that looks wrong?